This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolzt, M. Articles by Eichler, H.-G. Search for Related Content PubMed PubMed Citation Articles by Wolzt, M. Articles by Eichler, H.-G.

Hemodynamic Effects of Parathyroid Hormone-Related Peptide-(1–34) in Humans¹

Department of Clinical Pharmacology (M.W., L.S., G.D., G.Z., J.E., H.-G.E.), the Institute of Medical Physics (L.S.), and the Department of Medical and Chemical Laboratory Diagnostics (S.K.), Vienna University, Vienna, Austria

Address all correspondence and requests for reprints to: Dr. Michael Wolzt, Klinische Pharmakologie, Allgemeines Krankenhaus Wien, Währingergürtel 18–20, A-1090 Vienna, Austria.

It has been suggested that PTH-related peptide-(1–34) (PTHrP) is a regulator or modulator of regional or systemic cardiovascular function with varying vasodilating actions in different species. We have studied the cardiovascular pharmacodynamic profile of PTHrP in healthy humans.

In a double blind, placebo-controlled, cross-over study design, eight healthy subjects were assigned to stepwise increased iv doses of PTHrP. In addition, a dose-response curve to PTHrP was constructed in a dorsal hand vein in eight subjects.

PTHrP dose-dependently increased pulse rate and renal plasma flow by more than 50% (P < 0.0001 for both parameters, by ANOVA), but only a small venodilating response was seen in hand vein experiments, and no effect was noted on mean arterial blood pressure or cardiac inotropic performance.

Although it is unlikely that PTHrP regulates systemic hemodynamics, its chronotropic effect and its potent action on renal plasma flow may represent the primary cardiovascular physiological targets of action.

This article has been cited by other articles:

				H. Plotkin, C. Gundberg, M. Mitnick, and A. F. Stewart Dissociation of Bone Formation from Resorption during 2-Week Treatment with Human Parathyroid Hormone-Related Peptide-(1-36) in Humans: Potential as an Anabolic Therapy for Osteoporosis J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2786 - 2791. [Abstract] [Full Text]

				P. L. Selvais, J. E. Donckier, L. Rousseau, S. A. Ahn, J.-M. Ketelslegers, and M. F. Rousseau Hemodynamic Effects of Parathyroid Hormone-Related Peptide: Is There a Pathophysiological Relevance? J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 1043a - 1044. [Full Text]